Like Xerox, but instead of office copiers, they lease extremely advanced radiosurgery and radiation therapy equipment to hospitals.

A "Netflix for advanced cancer treatment equipment," providing hospitals with access to cutting-edge radiosurgery and radiation therapy machines without the massive upfront purchase.

• Gamma Knife Equipment Leasing: Leases radiosurgery equipment, specifically Gamma Knife units, to healthcare providers for non-invasive brain treatments.
• Gamma Knife Unit Financing: Provides financing services specifically for Leksell Gamma Knife units.
• Proton Beam Radiation Therapy (PBRT) Services: Offers direct proton beam radiation therapy services at facilities in Orlando, Florida, and Long Beach, California.
• Customer Support Services: Provides planning, installation, reimbursement, and marketing support to its healthcare provider customers.

American Shared Hospital Services (AMS) primarily sells to other companies, specifically various types of health care providers.

Its major customers are:

• Hospitals: Large medical institutions that utilize AMS's radiosurgery and radiation therapy equipment, such as Gamma Knife units and Proton Beam Radiation Therapy (PBRT) systems, to provide advanced treatments to their patients.
• Medical Centers/Clinics: Specialized medical facilities that offer radiation oncology or neurosurgery services and lease equipment from AMS to expand their treatment capabilities.

• Elekta AB (STO: EKTA B)
• Mevion Medical Systems, Inc.

1. Changes to CMS Reimbursement Rates or Methodology: A significant portion of the company's revenue and the demand for its equipment leasing and direct patient care services are dependent on reimbursement rates from government programs like Medicare (Centers for Medicare & Medicaid Services - CMS) and private insurers. Unfavorable changes to these rates or the methodologies used for reimbursement for Gamma Knife, proton therapy, and other advanced radiation therapy services could directly and adversely impact the profitability of American Shared Hospital Services and its healthcare provider partners, thereby affecting AMS's business model and financial results.
2. Technological Obsolescence and Intense Competition: American Shared Hospital Services leases state-of-the-art radiosurgery and radiation therapy equipment, such as Gamma Knife and Proton Beam Radiation Therapy (PBRT) systems. The rapid pace of technological advancements in the medical equipment industry poses a risk that the company's existing equipment could become outdated or less competitive. While American Shared Hospital Services' business model often transfers the risk of technological obsolescence from the medical center to the company, this means AMS itself bears the burden of ensuring its offerings remain current and competitive. The market for these advanced therapies is also subject to intense competition from other equipment providers and alternative treatment modalities, which could impact demand for AMS's services.
3. Financing and Liquidity Risks: American Shared Hospital Services operates in a capital-intensive industry, requiring substantial investment in medical equipment. The company's ability to maintain and expand its equipment fleet, as well as its overall operations, is dependent on access to financing and maintaining sufficient liquidity. A notable risk in this area is evidenced by the company receiving a notice of default from its lender in December 2025 due to failing to maintain required minimum unrestricted cash and cash equivalents. This highlights the criticality of managing debt obligations and maintaining adequate financial resources.

American Shared Hospital Services (AMS) operates in two primary addressable markets: radiosurgery equipment leasing, specifically for Gamma Knife stereotactic radiosurgery, and proton beam radiation therapy (PBRT) services.

Gamma Knife Stereotactic Radiosurgery Market

The global market for Gamma Knife is valued at several hundred million U.S. dollars. In 2024, the global Gamma Knife market size was approximately USD 468.22 million and is projected to reach USD 691.78 million by 2032, exhibiting a compound annual growth rate (CAGR) of 5.00%. Another report estimated the global Gamma Knife market at USD 470.3 million in 2023, with a projection to reach USD 742.3 million by 2033 at a CAGR of 5.2%.

North America is a significant region in the global Gamma Knife market, expected to hold the largest market share, with the U.S. being a leading contributor due to advanced neurosurgical infrastructure and high healthcare spending.

Proton Beam Radiation Therapy Market

The global market for proton therapy, including systems and services, is considerably larger, valued in the billions of U.S. dollars. The global proton therapy systems market size was US$ 1.52 billion in 2024 and is forecast to rise to US$ 1.66 billion by 2025. It is expected to surpass US$ 3.72 billion by 2034, growing at a CAGR of 9.44%. Other estimates place the global proton therapy market at approximately USD 572.5 million in 2024, projected to reach around USD 1,995.62 million by 2034 with a CAGR of 13.30%. Additionally, the global proton therapy market was valued at USD 1.57 billion in 2023 and is predicted to grow to around USD 5.86 billion by 2032.

North America is a dominant region in the proton therapy market. In 2024, North America held approximately 40% of the proton therapy systems market revenue share. The North America proton therapy market size was calculated at USD 246.18 million in 2024 and is expected to grow at a CAGR of 13.42%. North America's leadership in this market is attributed to rising cancer cases and technological advancements.

American Shared Hospital Services (AMS) is expected to drive future revenue growth over the next 2-3 years through several strategic initiatives focused on expanding its direct patient care services, technological advancements, and geographical footprint.

1. Expansion into Direct Patient Care Services through Strategic Acquisitions: American Shared Hospital Services is actively transitioning from primarily leasing equipment to becoming a direct provider of radiation therapy treatment services. This shift is a significant revenue driver, exemplified by the acquisition of a 60% majority interest in three Rhode Island radiation therapy centers in May 2024. This acquisition led to substantial revenue growth in the direct patient services segment, with a 253% increase in fiscal year 2024 and a 224% increase in the first quarter of 2025. The company continues to focus on business development and operational efficiencies within this segment.
2. Growth in Proton Beam Radiation Therapy (PBRT): The company is investing in the expansion of its Proton Beam Radiation Therapy offerings. A notable driver is the Certificate of Need (CON) approval received in December 2024 for a subsidiary to construct and operate a freestanding PBRT system in Johnston, Rhode Island. This facility is anticipated to begin treating patients in 36-39 months and represents a significant technological advancement in cancer care, creating greater access to this specialized treatment in the Northeast.
3. International Expansion, Particularly in Latin America: American Shared Hospital Services is expanding its international presence as a key revenue growth strategy. This includes the launch of new radiation therapy operations in Puebla, Mexico, which contributed to significant growth in the direct patient services segment in 2024. Additionally, the company expects long-term growth from a new Esprit Gamma Knife center being installed in Guadalajara, Mexico, with operations projected to start in late 2025 or the second quarter of 2026. The company also noted revenue growth in Peru and Ecuador in fiscal year 2024.
4. Modernization and Strategic Placement of Gamma Knife Systems: While the equipment leasing segment, including Gamma Knife operations, has seen some fluctuations, the company is focused on upgrading existing Gamma Knife systems and securing long-term lease extensions with health systems. For instance, a 10-year extension for an upgraded Gamma Knife system has been signed. This strategy aims to sustain and enhance revenue from its core Gamma Knife business through modern technology and strategic placements like the new Esprit in Guadalajara.

Share Repurchases

American Shared Hospital Services has shown minimal to no significant share repurchases over the last 3-5 years. The trailing twelve months (TTM) Buyback Yield stands at 0%. Over the past five years, the median Buyback Yield for the company was 0%, with the highest recorded at 0% and the lowest at -0.04% in March 2022.

Share Issuance

The number of shares outstanding for American Shared Hospital Services increased by 1.57% in one year. As of December 30, 2024, the company had 6.54 million shares outstanding.

Capital Expenditures

American Shared Hospital Services reported capital expenditures of -$14.28 million in the last 12 months. The latest trailing twelve months (TTM) Capital Expenditure to Operating Cash Flow (CapEx/OCF) stands at 343.06%. Over the past five years, the average CapEx/OCF was 345.43%, reaching a high of 4576.65% on December 31, 2024. These capital expenditures are primarily focused on acquiring and maintaining radiosurgery and radiation therapy equipment, such as Gamma Knife and proton beam radiation therapy systems, which are central to the company's leasing business.